Biomarkers of Risk for Colorectal Neoplasia (Team Project #2)
- Hanash, Samir — The University of Texas MD Anderson Cancer Center
- Liebler, Daniel — Vanderbilt Medical Center
- Lampe, Paul — Fred Hutchinson Cancer Research Center
- Srivastava, Sudhir — National Cancer Institute
- Getzenberg, Robert H. — Johns Hopkins University
- Grady, William — Fred Hutchinson Cancer Research Center
- Markowitz, Sanford — Case Western Reserve University
- Schoen, Robert E. — University of Pittsburgh Cancer Institute
Investigators in the colon section of EDRN have a mutual interest in developing markers that would identify individuals at increased risk for colon neoplasia. Identifying biomarkers of risk is a high priority, because markers would offer the promise of guiding or tailoring expensive interventions such as colonoscopy to the target population most likely to benefit. The goal of this project is to evaluate biomarkers in normal colonic mucosa to determine their relationship to the occurrence of short- and long-term colorectal neoplasia. Candidate markers have been proposed by participating investigators based on promising preliminary data. The purpose of this team project is to evaluate these markers in a common, tissue-based reference set, under a uniform, structured protocol. All markers will be evaluated in a similar, stepwise fashion. Step 1: To assess the reproducibility and variability of marker expression within individuals, marker expression will be evaluated in duplicate samples from the same region of the colon and in 3 different sites around the colon, the rectum, left and right colon. Step 2: To characterize the inter-subject variability in marker expression by disease phenotype, differences in marker expression in normal colonic mucosa between subjects with and without adenomatous polyps will be compared. Step 3: To examine the relationship between marker expression and long-term adenoma recurrence, marker expression will be compared among subjects with baseline adenomas who have a recurrence of adenomatous polyps compared to those who do not recur. The markers to be tested include methylated genes, 15-PGDH mRNA, creatine kinase B, and proteomic markers in tissue lysates evaluated by antibody array and via liquid chromatography-multiple reaction monitoring mass spectrometry. These efforts can potentially identify markers that stratify or delineate individuals who may benefit from chemoprevention or require more intensified surveillance regimens. By enhancing the evidence supporting a field effect of cancer risk and by characterizing the molecular events involved, these markers could assist in the rational allocation of colonoscopy resources, a priority in colorectal cancer screening and surveillance.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.